You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 4, 2025

Details for Patent: 11,382,926


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,382,926 protect, and when does it expire?

Patent 11,382,926 protects VEKLURY and is included in one NDA.

Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in twenty-three countries.

Summary for Patent: 11,382,926
Title:Methods for treating Arenaviridae and Coronaviridae virus infections
Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: ##STR00001## wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
Inventor(s): Clarke; Michael O'Neil Hanrahan (Redwood City, CA), Feng; Joy Yang (Hillsborough, CA), Jordan; Robert (Foster City, CA), Mackman; Richard L. (Millbrae, CA), Ray; Adrian S. (Burlingame, CA), Siegel; Dustin (Half Moon Bay, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:17/222,066
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 11,382,926: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 11,382,926, titled "Methods for treating Arenaviridae and Coronaviridae virus infections," is a significant patent that addresses the treatment of specific viral infections. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Publication Number and Authority

The patent, numbered US11,382,926B2, was granted by the United States Patent and Trademark Office (USPTO)[2].

Prior Art and Legal Status

The patent is active, indicating that it is currently in force. However, the legal status is subject to change and should be verified through official channels. The prior art keywords include compounds, alkyl groups, and specific chemical structures like isobutyl and n-propyl groups[2].

Scope of the Invention

Methods for Treating Viral Infections

The patent describes methods for treating infections caused by Arenaviridae and Coronaviridae viruses. These methods involve administering nucleosides and prodrugs thereof, which are designed to target and inhibit the replication of these viruses. The invention is crucial in the field of virology, particularly in the context of emerging and re-emerging viral diseases[2].

Claims

Detailed Claims Analysis

The patent includes several claims that define the scope of the invention. Here are some key aspects:

  • Claim 1: This claim typically defines the broadest scope of the invention, often describing the general method of treating viral infections using the specified nucleosides and prodrugs.
  • Dependent Claims: Subsequent claims usually narrow down the scope by specifying particular compounds, dosages, administration methods, and patient populations. For example, claims might detail specific alkyl groups or the structure of the nucleosides[2].

Chemical Structures and Compounds

The patent includes detailed descriptions of chemical structures, such as isobutyl, n-propyl, and isopentyl groups. These structures are critical in defining the novelty and non-obviousness of the invention[2].

Patent Landscape

Global Patent System

The patent is part of a broader global patent system. To understand its place, one must consider international patent databases and the harmonization efforts among intellectual property offices. Tools like the Global Dossier and Common Citation Document (CCD) facilitate the search and analysis of related patents across different jurisdictions[1].

Related Patents and Applications

Searching databases such as the European Patent Office's esp@cenet, the Japan Patent Office, and the World Intellectual Property Organization's PATENTSCOPE can reveal related patents and applications. This helps in understanding the competitive landscape and potential overlaps or conflicts[1].

Technological Trends

The USPTO classifies patents into various technological fields. Patents related to medical treatments, particularly those involving nucleosides and antiviral therapies, fall under categories such as chemistry and pharmaceuticals. The trend in these fields shows an increasing focus on biotechnology and pharmaceutical innovations, reflecting the growing importance of these areas in addressing global health challenges[4].

Economic and Innovation Impact

Patent Activity and Trends

The USPTO awarded 309,000 utility patents in 2018, with a significant portion in the fields of electrical engineering and biotechnology. This indicates a strong innovation ecosystem, where patents like US11,382,926 contribute to the advancement of medical treatments and public health[4].

Intellectual Property Protection

Patents like US11,382,926 provide inventors with exclusive rights to their inventions, encouraging further research and development. This protection is crucial for the commercialization of new treatments and the investment in R&D by pharmaceutical companies[4].

Search and Analysis Tools

USPTO Resources

The USPTO offers several tools for searching and analyzing patents, including the Patent Public Search tool, Global Dossier, and the Patent Examination Data System (PEDS). These resources are essential for conducting thorough searches and understanding the prior art and patent family related to US11,382,926[1].

International Databases

Access to international patent databases, such as those provided by the European Patent Office, Japan Patent Office, and World Intellectual Property Organization, is vital for a comprehensive analysis. These databases offer machine translations and full-text searches, facilitating global patent research[1].

Conclusion

United States Patent 11,382,926 represents a significant advancement in the treatment of viral infections caused by Arenaviridae and Coronaviridae. The detailed analysis of its scope, claims, and the broader patent landscape highlights its importance in the field of virology and pharmaceutical innovation.

Key Takeaways

  • Invention Scope: The patent covers methods for treating viral infections using specific nucleosides and prodrugs.
  • Claims Analysis: The claims define the invention's scope, including chemical structures and administration methods.
  • Patent Landscape: The patent is part of a global system, with related patents and applications searchable through various international databases.
  • Economic Impact: The patent contributes to the innovation ecosystem, particularly in biotechnology and pharmaceuticals.
  • Search Tools: Utilizing USPTO and international databases is crucial for thorough patent research.

FAQs

Q: What is the main focus of United States Patent 11,382,926?

A: The main focus is on methods for treating infections caused by Arenaviridae and Coronaviridae viruses using nucleosides and prodrugs.

Q: How can one search for related patents globally?

A: One can use tools like the Global Dossier, Common Citation Document (CCD), and international patent databases such as esp@cenet and PATENTSCOPE.

Q: What is the significance of chemical structures in this patent?

A: The chemical structures, such as isobutyl and n-propyl groups, are critical in defining the novelty and non-obviousness of the invention.

Q: How does this patent fit into the broader technological trends?

A: It fits into the growing trend of biotechnology and pharmaceutical innovations, particularly in addressing global health challenges.

Q: What resources are available for searching and analyzing patents like US11,382,926?

A: Resources include the USPTO's Patent Public Search tool, Global Dossier, PEDS, and international patent databases.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Google Patents - US11382926B2: https://patents.google.com/patent/US11382926B2/en
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. NSF - Invention: U.S. and Comparative Global Trends: https://ncses.nsf.gov/pubs/nsb20204/invention-u-s-and-comparative-global-trends

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 11,382,926

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc VEKLURY remdesivir POWDER;INTRAVENOUS 214787-001 Oct 22, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Gilead Sciences Inc VEKLURY remdesivir SOLUTION;INTRAVENOUS 214787-002 Oct 22, 2020 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,382,926

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016323604 ⤷  Subscribe
Australia 2020233714 ⤷  Subscribe
Australia 2023200990 ⤷  Subscribe
Brazil 112018005048 ⤷  Subscribe
Brazil 122020020217 ⤷  Subscribe
Canada 2998189 ⤷  Subscribe
China 108348526 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.